Hutchison China MediTech Ltd at Morgan Stanley Healthcare Conference Transcript
Great. So good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Just quickly before we get started, I need to read an important disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up your own copy at the registration desk. So, Christian, pleased to have you here. Christian, CEO of Chi-Med. I thought, just quickly to get us started, there's been a wave of new biotech companies in China. You've obviously as a company had a long history in China. So maybe -- for the audience, maybe just describe to us what you see as your advantages given your history of operating in that market.
Great. Thanks, Matt. So Hutchison China MediTech or Chi
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |